Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
about
Immunotherapy of Childhood SarcomasOsteosarcoma Overview.A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.Spontaneously occurring tumors of companion animals as models for human cancer.Review of mifamurtide in the treatment of patients with osteosarcoma.Toward a drug development path that targets metastatic progression in osteosarcoma.Immunotherapeutic Intervention against Sarcomas.Current treatment of osteosarcoma.Liposomal MTP-PE.Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review.Liposomes: realizing their promise.Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investmentLiposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.The Current and Future Therapies for Human Osteosarcoma.Using macrophage activation to augment immunotherapy of established tumours.Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcomaMetastatic osteosarcoma: a review of current issues in systemic treatment.Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.Mifamurtide for the treatment of nonmetastatic osteosarcomaThe immunotherapy of canine osteosarcoma: a historical and systematic review.Immunotherapy in Sarcoma: Future Horizons.Immune Therapy for Sarcomas.Prevention of experimental endotoxin shock by a monocyte activator.Immune-based therapies for sarcoma.Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.Manipulation of Innate Immunity for Cancer Therapy in Dogs.A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1.Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.
P2860
Q26795369-4117AC4F-60AE-42A7-BCC3-C5BB263DE495Q33725511-E0796762-E864-47A2-B283-40F059C07C7AQ33889409-0B918A86-FC4D-4855-9636-879BFF403A2DQ33927360-83D615C6-2393-4CFB-A361-07942B32DCDFQ33947618-5837895D-D078-42CF-8D15-A8D07F4D06C1Q34052760-8C11D7D5-DB87-4202-ADCE-A130D8914628Q34196481-28A5EF3B-5323-4076-A4DD-19CF155C9593Q34242261-B816D41C-AAB6-471B-8E35-83BCC4F4A115Q34725019-A4F0D720-F7BB-4EA0-840E-ACD43E3B5104Q34996698-352C5E92-0F52-4F52-A5DA-8F784B0C7EAFQ35163616-75AFC3E6-3B24-4F02-BC66-9C5B30D1223DQ35550017-60D2287D-003C-4604-99D0-8A1E8BAF2353Q35945493-BB5C1552-B829-41A8-9DE5-0B264BD18A3FQ35958048-6DADD774-BEA2-44AF-8092-5E0805B7FC2AQ36512499-9428A76A-8930-4D94-A4C4-CF601D9DBF2BQ36514299-468B1931-C11D-4D9A-BAD6-CB34F672635AQ36747346-1542C562-AD33-4AED-9112-024088E0B1BEQ37125088-34F8DB9F-FBE6-49C0-9125-92F0578B78A5Q37180881-97AEA4C7-6531-4B5D-B8A2-8BC7D18C9EE2Q37439345-22CB663E-8BDD-488A-9A9F-B40F6DE20C9CQ37827876-085EA57F-1D37-4CDA-B149-6191CA529D48Q38451770-57E4193F-139F-4EB5-9507-3F093BF741F3Q38596093-0A6C0374-DA86-42CA-8ECB-8CA792F11795Q38742533-DBAC70BF-4B54-4A2A-A9EE-D2352C67264FQ39780812-57BCACE8-2172-4BA3-B926-49ADE90E4C5AQ41931033-C97106CB-F8B5-41CD-80FB-9793985E8097Q47096040-B4FD7E2C-E7FD-414E-AFA7-B2378F13E9FFQ47137850-8722C867-764C-4E9E-9A31-CE40CEFB2A96Q47967532-43EED14A-0907-4032-86CC-EBFFD3F8233CQ49364445-0F7D35CB-856D-4EE2-9590-655083D6485CQ55323964-D3E80C10-2178-4B39-A72B-BA1853015C71
P2860
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Phase II study of liposomal mu ...... tion following administration.
@ast
Phase II study of liposomal mu ...... tion following administration.
@en
Phase II study of liposomal mu ...... tion following administration.
@nl
type
label
Phase II study of liposomal mu ...... tion following administration.
@ast
Phase II study of liposomal mu ...... tion following administration.
@en
Phase II study of liposomal mu ...... tion following administration.
@nl
prefLabel
Phase II study of liposomal mu ...... tion following administration.
@ast
Phase II study of liposomal mu ...... tion following administration.
@en
Phase II study of liposomal mu ...... tion following administration.
@nl
P2093
P1476
Phase II study of liposomal mu ...... tion following administration.
@en
P2093
E S Kleinerman
N L Seibel
R S Benjamin
P304
P356
10.1200/JCO.1992.10.8.1310
P407
P577
1992-08-01T00:00:00Z